Neurocrine is beefing up its pipeline, splurging $50M on rights to an epilepsy drug
Neurocrine has stepped up with $50 million in cash and a bundle of biobucks to bag rights to an early-stage epilepsy drug out of Xenon Pharmaceuticals.
Neurocrine $NBIX is forking over the cash in an upfront and equity stake in exchange for an exclusive license to XEN901, a Nav1.6 sodium channel inhibitor. The deal also covers preclinical drugs in the same pathway along with dual Nav1.2/1.6 inhibitors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
